Sign In
Buy ARTL
$0.770
+0.0148 (+1.96%)
At Close: Jul 31, 2026
Artelo Biosciences Provides Business Update and Reports Second Quarter 2025 Financial Results
08:00am, Wednesday, 13'th Aug 2025
SOLANA BEACH, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop t
Extends Patent Protection Through December 2041 ART27.13 is Currently under Evaluation in a Phase 2 Study for the Treatment of Cancer-Related Anorexia SOLANA BEACH, Calif., Aug. 11, 2025 (GLOBE NEWSWI
Lead investor Bartosz Lipiński, previously Head of Engineering at Solana Labs, will serve as a technical partner CUBE selected to secure storage, staking, and active DeFi execution of Artelo's digita
MHRA indicated ART12.11 may be a candidate for accelerated development via the Innovative Licensing and Access Pathway MHRA indicated ART12.11 may be a candidate for accelerated development via the In
ART26.12, a Novel FABP5 Inhibitor, Demonstrates Sustained Analgesic Effects Without Tolerance ART26.12, a Novel FABP5 Inhibitor, Demonstrates Sustained Analgesic Effects Without Tolerance
Artelo Biosciences Analyst See It As An Emerging Biotech
03:06pm, Tuesday, 08'th Jul 2025
Analyst Jason Kolbert upgrades Artelo to Buy with a new $20 price target citing multiple promising drug assets.
Artelo Biosciences Announces Positive Preclinical Efficacy with ART12.11 in Stress-Induced Depression Model
07:45am, Monday, 07'th Jul 2025
ART12.11, the Patented CBD:TMP Cocrystal, Demonstrates Potent Antidepressant-Like Activity and Cognitive Benefits Over Leading SSRI
First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market SOLANA BEACH, Calif., June 30, 2
Artelo Biosciences Announces $1.425 Million At-the-Market Private Placement Financing
08:00am, Thursday, 26'th Jun 2025
SOLANA BEACH, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treat
Artelo Biosciences Announces Reverse Stock Split
08:30am, Wednesday, 11'th Jun 2025
SOLANA BEACH, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treat
Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study
09:00am, Thursday, 05'th Jun 2025
SOLANA BEACH, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treat
New Independent Review Paper Strengthens Therapeutic Rationale for Artelo's FABP Inhibitor Program in Anxiety and Depression
09:00am, Monday, 02'nd Jun 2025
SOLANA BEACH, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treat
ART26.12 Phase 1 in healthy volunteers completes enrollment with clinical data announcement expected this quarter ART26.12 Phase 1 in healthy volunteers completes enrollment with clinical data annou
New Strong Sell Stocks for April 10th
06:45am, Thursday, 10'th Apr 2025
ASTS, ASEKY and ARTL have been added to the Zacks Rank #5 (Strong Sell) List on April 10, 2025.
Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025
08:30am, Monday, 31'st Mar 2025
SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop tr
